

Product Datasheet

(S)-2-(4-(4-(4-(5-(1-amino-1-(4-fluorophenyl)ethyl)pyrimidin-2-yl)piperazin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)-1H-pyrazol-1-yl)ethan-1-ol

Catalog No. **BP-02026** · CAS **2505078-08-8** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-09-11**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target c-Kit	Research area Cancer
------------------------	--------------------------------

Molecular formula **C₂₇H₂₉FN₁₀O**

Molecular weight **528.5840**

STRUCTURE



DESCRIPTION

A tyrosine kinase inhibitor.

BIOLOGICAL ACTIVITY

BLU 263, is a next-generation tyrosine kinase inhibitor (KIT) being developed by Blueprint Medicines for the treatment of indolent systemic mastocytosis (SM).

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Dave N, et al. Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteers[C]//Cancer Res (AACR Annual Meeting Abstracts). 2021, 122.

[2]. Mariana Castells, et al. A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome. Allergy and Clinical Immunology. 2022, 149 (2).

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.